EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma

Danny Rischin, Sandro Porceddu, Fiona Day, Daniel P Brungs, Hayden Christie, James E Jackson, Brian N Stein, Yungpo Bernard Su, Rahul Ladwa, Gerard Adams, Samantha E Bowyer, Zulfiquer Otty und 35 weitere

New England Journal of Medicine · 21.08.2025 · 393 (8) · 774-785

DOI: 10.1056/nejmoa2502449 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 21.08.2025. Verfasst von Danny Rischin und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Squamous CellNeoplasm Recurrence, LocalSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind Method

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalcemiplimab

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.
  • Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW, Australia.
  • Graduate School of Medicine, University of Wollongong, Wollongong, NSW, Australia.

ORCID-Profile: Alexander Stratigos

Förderung

  • Regeneron Pharmaceuticals

Zitieren

APA

Rischin, D., Porceddu, S., Day, F., Brungs, D. P., Christie, H., Jackson, J. E., Stein, B. N., Su, Y. B., Ladwa, R., Adams, G., Bowyer, S. E., Otty, Z., Yamazaki, N., Bossi, P., Challapalli, A., Hauschild, A., Lim, A. M., Patel, V. A., Walker, J. L., …, & C-POST Trial Investigators (2025). Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine, 393(8), 774-785. https://doi.org/10.1056/nejmoa2502449

Vancouver

Rischin D, Porceddu S, Day F, Brungs DP, Christie H, Jackson JE, et al. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine. 2025;393(8):774-785. doi:10.1056/nejmoa2502449

BibTeX
@article{Rischin2025,
  author = {Rischin, Danny and Porceddu, Sandro and Day, Fiona and Brungs, Daniel P and Christie, Hayden and Jackson, James E and Stein, Brian N and Su, Yungpo Bernard and Ladwa, Rahul and Adams, Gerard and Bowyer, Samantha E and Otty, Zulfiquer and Yamazaki, Naoya and Bossi, Paolo and Challapalli, Amarnath and Hauschild, Axel and Lim, Annette M and Patel, Vishal A and Walker, Joanna L and De Liz Vassen Schurmann, Maite and Queirolo, Paola and Cañueto, Javier and Ferreira da Silva, Flavio Augusto and Stratigos, Alexander and Guminski, Alexander and Lin, Charles and Damian, Fernanda and Flatz, Lukas and Taylor, Anne E and Carr, David R and Harris, Samuel and Kirtbaya, Dmitry and Quereux, Gaëlle and Rutkowski, Piotr and Basset-Seguin, Nicole and Khushalani, Nikhil I and Robert, Caroline and Ju, Haisong and Joseph, Camryn and Bansal, Shikha and Chen, Chieh-I and Seebach, Frank and Yoo, Suk-Young and Lowy, Israel and Goncalves, Priscila and Fury, Matthew G and C-POST Trial Investigators, C-POST Trial Investigators},
  title = {Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {8},
  pages = {774--785},
  doi = {10.1056/nejmoa2502449}
}
Kostenlos starten →